Navigation Links
CutisPharma Launches New Prescription Mouthwash Kits Expanding Product Line

WOBURN, Mass., Jan. 5, 2011 /PRNewswire/ -- CutisPharma, Inc. announced the introduction of FIRST® - Duke's Mouthwash and FIRST® - Mary's Mouthwash compounding kits. These products complete the FIRST® Magic Mouthwash line for CutisPharma. The product line already includes FIRST® - Mouthwash BLM, and FIRST® - BXN Mouthwash.  The active ingredients in FIRST® - Duke's Mouthwash are comparable to those found in the most routinely prepared formulation of Magic Mouthwash containing Benadryl®, hydrocortisone, and nystatin. The active ingredients in FIRST® - Mary's Mouthwash are comparable to those found in the most routinely prepared formulation of Magic Mouthwash containing Benadryl®, hydrocortisone, nystatin, and tetracycline. The kits are made for one patient and include pre-weighed powders, and a pre-measured suspension. With FIRST® - Mouthwash Kits, the pharmacist needs only to add the powders to the liquid suspension, shake, and then dispense to the patient.

"By launching FIRST® - Duke's and Mary's, physicians now have four of the more commonly prescribed magic mouthwash prescriptions available in a kit," said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc.  "The Company now offers an expanded line of Magic Mouthwash formulations for patients, physicians, and pharmacists."

FIRST® products save dispensing time, and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction.  Using FIRST® Mouthwash kits, the pharmacist can compound a prescription faster than those prepared in the conventional way.  A single NDC number assigned for the entire Kit facilitates the third party reimbursement process, and reduces audit- related adjustments.

CutisPharma now has twelve proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, and four Magic Mouthwash kits.  Several more compounding kits are in the planning stages.  FIRST® Unit-of-Use Prescription Compounding Kits facilitates compliance with United States Pharmacopeia (USP) Chapter <795>.

The FDA estimates that each year in the United States approximately 30 million retail and hospital outpatient prescriptions are prepared through "compounding," a means by which a pharmacist prepares a customized medication according to a doctor's prescription to meet an individual patient's medical need.  About 1% of all prescriptions are compounded; and the U.S. market alone for compounding, at the consumer level, represents an estimated $1 billion annually.  

About CutisPharma

CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FIRST®  Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Three U.S. patents have been issued to the Company with several additional patents pending.

For more information please visit our website at

SOURCE CutisPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CutisPharma Announces Issuance of an Additional Patent for Suppository Compounding
2. CareFusion Launches EnVe Ventilator, Weighing 10 Times Less Than Traditional Critical Care Ventilators
3. Beaumont Hospital Launches Study of Single-Dose Radiation Treatment for Prostate Cancer
4. UBM Canon Launches Medical Manufacturing Events in India and Brazil
5. Ambry Genetics Launches Illumina HiSeq 2000 Next Generation Sequencing Services
6. Clarient Launches Insight® Dx Mammostrat® Breast Cancer Recurrence Test
7. CareFusion Launches Respiratory Airway Adapter to Improve Patient Safety and Reduce Hospital Costs
8. UBM TechInsights Launches Product Teardowns for Medical Electronics
9. Purdue Pharma L.P. Re-launches Partners Against Pain Website
10. CareFusion Launches Next-Generation Clinical Pulmonary and Cardiopulmonary Diagnostics Software
11. BugLab Launches Worlds First Handheld Non-invasive Optical Density Sensor
Post Your Comments:
(Date:11/24/2015)... , Nueva York , ... Biomedical Devices (ABD), fabricante del Avery Breathing Pacemaker ... Anders Jonzon , MD; Ph.D. como consultor clínico. ...   --> Foto - ... --> El doctor Jonzon es un fisiólogo ...
(Date:11/24/2015)... 24, 2015 --> ... Biologics Market by Product Type (Bone Graft, Bine Graft Substitute, ... Fusion, Posterior Lumbar Interbody Fusion), End User, and Geography - ... was valued at $1.90 Billion in 2014 and is expected ... 4.4% during the forecast period of 2015 to 2020. ...
(Date:11/24/2015)... FRAMINGHAM, Mass. , Nov. 24, 2015   ... leading innovator of less-invasive, miniaturized circulatory support technologies that ... announced that President and Chief Executive Officer Doug ... Jaffray 27 th Annual Healthcare Conference on December ... being held December 1-2 in New York ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA ... Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. ... traditional cutting tools, such as the scalpel and high-speed drill, which can both cause ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Charitable giving ... charitable donations are made in the last five weeks of the year totalling over ... created in 2012 to connect the nation’s charities with those individuals who want to ...
(Date:11/24/2015)... (PRWEB) , ... November 25, 2015 , ... ... technologies and development solutions for drugs, biologics, consumer health and global clinical supply ... present at the upcoming Clinical Trial Supply East Asia Conference, to be held ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Preparing for ... p.m. – 3:00 p.m. EST, , FDA has long asserted that ... regulations apply to performing the tests and do not meet the device regulations. , ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... LENR HHT Bolier Reactor System. Brillouin is the developer of renewable energy technologies ... low energy nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler ...
Breaking Medicine News(10 mins):